A New Era for Patients with NMOSD, including Children

Course Description

• To learn current diagnostic criteria for NMO/NMOSD.
• To know updated information on the diagnostic biomarkers and appropriate laboratory techniques.
• To learn current rescue therapies for acute events, and introducing novel relapse prevention strategies for patients with NMOSD.

Learning Objectives

1. Learn new clinical and neuroimaging diagnostic criteria for NMO/NMOSD and corresponding biomarkers.
2. Receive updated information on current rescue therapies for severe acute CNS events, and learn on relapse prevention strategies, including novel immunosuppressive drugs.

Impact Statements

1. Make appropriate diagnosis of NMOSD.
2. Recognize relevant data about treatment options that should be considered for the correct treatment of acute events and relapse prevention with immunosuppression in children.

Organizer:
Silvia N. Tenembaum, MD; National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina

Introduction: Current Diagnostic Criteria of Neuromyelitis Optica Spectrum Disorders (NMOSD)
Silvia N. Tenembaum, MD
Dr. Juan P. Garrahan

Diagnostic Biomarkers of NMOSD: AQP4-IgG and MOG-IgG
Thaís Armangue, MD, PhD; IDIBAPS-Hospital Clinic, University of Barcelona, Sant Joan de Déu Children’s Hospital, University of Barcelona, Barcelona, Spain

Treatment of Acute Clinical Events
Andrea Savransky, MD; National Pediatric Hospital Dr. J. P. Garrahan, Buenos Aires, Argentina Wednesday, October 21 24 ICNA • CNS | San Diego 2020

Current Preventive Treatment Strategies for NMOSD
E. Ann Yeh, MD, MA, FRCPC; Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

New Era on Preventive Treatment of NMOSD: Recently Approved and Investigational Agents
Tanuja Chitnis, MD, FAAN; Harvard Medical School, Boston, Massachusetts, USA